PaxMedica Comments on Common Stock Volatility
Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) — via…
News
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone’s Intranasal ExoPTEN
Figs. 1A-B Diffusion Tensor Imaging and Measurements TORONTO and TEL AVIV, Israel, June 22, 2023…
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome
REDWOOD CITY, Calif., June 22, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper),…
Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation
Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients…
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in the…
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated….
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today…
Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”)…
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has…
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006)…
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical…
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes…
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter…
Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”)
Through a sponsorship agreement CCIC’s accredited Canadian Cannabis Syllabus will be made available to the…
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
ASLAN will receive up to $15 million in upfront and near-term payments and up to…
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase…